Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmina Kalabic

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
JAMA|January 22, 2025
Risankizumab for Ulcerative Colitis-ReplyEdouard Louis, Jasmina Kalabic, Edward V Loftus
Journal of Comparative Effectiveness Research|August 22, 2018
Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritisErin Murray, Alexandra Ellis, Yekaterina Butylkova, et al.
Clinical Pharmacokinetics|December 20, 2024
Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseRonilda D'Cunha, Tofial Azam, Jasmina Kalabic, et al.
Clinical Rheumatology|February 4, 2014
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 yearsDaniel J Kingsbury, Brigitte Bader-Meunier, Gina Patel, et al.
Clinical Therapeutics|February 7, 2021
Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous InjectionHoi-Kei Lon, Ling Cheng, Sai Nudurupati, et al.
The Journal of Rheumatology|September 3, 2018
Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and MethotrexateGurjit S Kaeley, Daryl K MacCarter, Aileen L Pangan, et al.
Rheumatology and Therapy|April 1, 2017
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Rheumatology and Therapy|May 6, 2017
Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
The Journal of Rheumatology|June 17, 2016
Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA TrialGurjit S Kaeley, Amy M Evangelisto, Midori J Nishio, et al.
Clinical Pharmacology in Drug Development|July 2, 2024
SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative ColitisSven Stodtmann, Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
JAMA|January 22, 2025
Risankizumab for Ulcerative Colitis-ReplyEdouard Louis, Jasmina Kalabic, Edward V Loftus
Journal of Comparative Effectiveness Research|August 22, 2018
Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritisErin Murray, Alexandra Ellis, Yekaterina Butylkova, et al.
Clinical Pharmacokinetics|December 20, 2024
Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseRonilda D'Cunha, Tofial Azam, Jasmina Kalabic, et al.
Clinical Rheumatology|February 4, 2014
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 yearsDaniel J Kingsbury, Brigitte Bader-Meunier, Gina Patel, et al.
Clinical Therapeutics|February 7, 2021
Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous InjectionHoi-Kei Lon, Ling Cheng, Sai Nudurupati, et al.
The Journal of Rheumatology|September 3, 2018
Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and MethotrexateGurjit S Kaeley, Daryl K MacCarter, Aileen L Pangan, et al.
Rheumatology and Therapy|April 1, 2017
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Rheumatology and Therapy|May 6, 2017
Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
The Journal of Rheumatology|June 17, 2016
Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA TrialGurjit S Kaeley, Amy M Evangelisto, Midori J Nishio, et al.
Clinical Pharmacology in Drug Development|July 2, 2024
SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative ColitisSven Stodtmann, Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, et al.
Pageof 4